Could Common Diabetes Medications Help Fight Leukemia?: – WEDNESDAY, Sept. 2, 2015 – – Common diabetes drugs will help eradicate drug-resistant cancer cells in a particular form of leukemia when put into standard treatment, a little new study suggests. Researchers found that patients with chronic myeloid leukemia who all received a glitazone – – a class of medication for type 2 diabetes – – combined with the standard CML medication imatinib remained disease-free for nearly five years. Imatinib, known as Gleevec commercially, boasts an impressive background in controlling chronic myeloid leukemia and allowing patients to lead virtually regular lives. But despite its effectiveness, dormant, drug-resistant leukemic cells lay in wait in bone marrow typically.The poster entitled, ‘Phase I dose-escalation, safety, and pharmacokinetic study on every week oral AEZS-112, a small molecule anti-cancers agent in patients with advanced cancer and lymphoma’, D.W. Northfelt, reviewed results of this Phase I study made to evaluate the protection, tolerability and pharmacokinetics of ascending dosages of AEZS-112 in sufferers with the above-mentioned types of cancer. Related StoriesCrucial switch in single DNA base predisposes children to intense form of cancerViralytics enters into scientific trial collaboration agreement with MSDMeat-rich diet may increase kidney tumor riskIn part I, 22 patients were studied on 7 dose levels which range from 13 to 800 mg/week.